Tags » ADT

Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. 498 more words

Management

Do men with mCRPC need to stay on ADT along with their abiraterone acetate?

On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). 389 more words

Management

The importance of 3 weeks ... before starting docetaxel along with ADT

A new study in BJU International has shown the importance of waiting at least 3 weeks after initiation of androgen deprivation therapy (ADT) until initiation of docetaxel chemotherapy in the treatment of men with newly diagnosed, metastatic, hormone-sensitive prostate cancer (mHSPC). 469 more words

Management

Abstract data type

We see a lot of abstract data type (ADT) in programming such as stack, queue,…

So why are they called ADT?

Well, lets take an example in real life, in which you are sitting in front of a TV, holding a remote control in your hand. 190 more words

Programming

Update on STAMPEDE data on abiraterone + ADT in M0 patients with HSPC

Three months ago, James et al. presented the overall survival data from the most recently completed arm of the STAMPEDE trial at the annual meeting of the American Society of Clinical Oncology (ASCO). 515 more words

Management

What is standard, first-line therapy for men with mHSPC today?

A presentation at the ongoing annual meeting of the European  Society of Medical Oncology (ESMO), in Madrid, Spain, has offered us data comparing abiraterone acetate + prednisone + ADT to docetaxel + ADT in the treatment of men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC). 380 more words

Management

Alzheimer's, dementia, and androgen deprivation therapy (again)

A new study has concluded that added risk for Alzheimer’s disease and dementia among Medicare patients with prostate cancer who were treated with androgen deprivation therapy (ADT) was minimal in men treated between 2001 and 2014. 407 more words

Management